Preview

User

Not a user? Register with this site Forgot your password?

Problems of Endocrinology

Advanced search

Anomalous lipoprotein-X in type 2 diabetes mellitus

https://doi.org/10.14341/probl201258418-21

Abstract

Type 2 diabetes mellitus (DM2) is the most common form of diabetes characterized by the disturbances of carbohydrate, protein, and lipid metabolism including dyslipidemia and elevation of the low-density lipoprotein (LDLP) levels. Lipoprotein-X (LP-X) represents an anomalous subclass of LDLP a distinctive feature of which is the high content of phospholipids and non-esterified cholesterol coupled with the low level of cholesterol ethers, triglycerides, and proteins. LP-X was detected in the blood of the patients with various diseases of the liver and biliary ducts associated with cholestasis. The results of our previous investigations suggest the presence of LP-X in the blood of the patients with familial Mediterranean fever and ischemic stroke complicated by concomitant diabetes mellitus. The objective of the present work was to elucidate whether LP-X actually occurs in the blood of the patients presenting with type 2 diabetes mellitus. We used the method of polyanionic precipitation of LDLP preliminarily separated by agar gel electrophoresis. The study has demonstrated for the first time the presence of LP-X in the blood of the patients with type 2 diabetes mellitus. Its possible pathogenetic role and mechanisms of LP-X generation in DM2 are discussed.

References

1. van Dieren S., Beulens J.W., van der Schouw Y.T., Grobbee D.E., Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010; 17: Suppl 1: S3-S8.

2. Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab 2003; 29: 6: S9-S18.

3. Switzer S. Plasma lipoproteins in liver disease. I. Immunologically distinct low-density lipoproteins in patients with biliary obstruction. J Clin Invest 1967; 46: 1855-1866.

4. Seidel D. Lipoproteins in liver disease. J Clin Chem Clin Biochem 1987; 25: 541-551.

5. Boyajyan A.S., Arakelyan A.A., Ayvazyan V.A. Lipoprotein-X in diseases. In Handbook of lipoprotein research. Ed. J.E. Rathbond. New York: Nova Science Publishers Inc. 2011.

6. Manukyan L., Boyajyan A., Arakelyan A., Ayvazyan V., Arakelova E., Sim R., Grigoryan G. Immunochemical composition of cryoglobulins generated in stroke. J Clin Immunol 2009; 29: 274-281.

7. Seidel D., Wieland H., Ruppert C. Improved techniques for assessment of plasma lipoprotein patterns. I. Precipitation in gels after electrophoresis with polyanionic compounds. Clin Chem 1973; 19: 737-739.

8. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.

9. Duncan B.B., Schmidt M.I., Pankow J.S., Ballantyne C.M., Couper D., Vigo A., Hoogeveen R., Folsom A.R., Heiss G. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003; 52: 1799-1805.

10. Huysman E., Mathieu C. Diabetes and peripheral vascular disease. Acta Chir Belg 2009; 109: 587-594.

11. Lynn E.G., Siow Y.L., Frohlich J., Cheung G.T., O K. Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa B. Kidney Int 2001; 60: 520-532.

12. Mine S., Okada Y., Tanikawa T., Kawahara C., Tabata T., Tanaka Y. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem Biophys Res Commun 2006; 344: 780-785.

13. Bláha V., Andrýs C., Smahelová A., Knízek J., Hyspler R., Solichová D., Bláha M., Zadák Z. Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: Relationship to cholesterol turnover. Pharmacol Res 2006; 54: 421-428.

14. Boyajyan A.S., Arakelova E.A., Ayvazyan V.A., Manukyan L.A. Interleukins and chemokines in acute ischemic stoke complicated and non-complicated with diabetes. Cytokin Inflamm 2008; 7: 41-45.

15. Mackay C.R. Chemokines: immunology's high impact factors. Nat Immunol 2001; 2: 95-101.

16. Di Napoli M., Arakelyan A., Boyajyan A., Godoy A., Papa F. The acute phase inflammatory response in stroke: systemic inflammation and neuroinflammation. In: Progress in Inflammation Research. New York: Nova Science Publishers Inc 2006.

17. Chang P.Y., Lu S.C., Su T.C., Chou S.F., Huang W.H., Morrisett J.D., Chen C.H., Liau C.S., Lee Y.T. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004; 45: 2116-2122.

18. Steinberg D., Witztum J.L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002; 105: 2107-2111.

19. Betteridge D.J., Illingworth D.R., Shepherd J. Lipoproteins in health and disease. UK Hodder Arnold 1999.


Review

For citations:

Ovsepian M.R., Ébragimzade M.G., Gabrielian A.B., Oganesian M.G., Gevorkian A.A., Mamikonian A.A., Boiadzhian A.S. Anomalous lipoprotein-X in type 2 diabetes mellitus. Problems of Endocrinology. 2012;58(4):18-21. https://doi.org/10.14341/probl201258418-21

Views: 671


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)

11, Dm. Ul’yanova str., Moscow, Russian Federation, 117292

Processing of personal data
supported by NEICON (Elpub lab)